Goldman Sachs
OBIO icon

Goldman Sachs’s Orchestra BioMed OBIO Stock Holding History

Goldman Sachs’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$660K Buy
155,242
+21,169
+16% +$90.1K ﹤0.01% 5401
2025
Q4 		$556K Buy
134,073
+110,443
+467% +$446K ﹤0.01% 5525
2025
Q3 		$58.6K Sell
23,630
-73,211
-76% -$202K ﹤0.01% 6153
2025
Q2 		$260K Buy
96,841
+48,112
+99% +$140K ﹤0.01% 5523
2025
Q1 		$209K Sell
48,729
-13,408
-22% -$66.7K ﹤0.01% 5622
2024
Q4 		$249K Buy
62,137
+20,098
+48% +$108K ﹤0.01% 5559
2024
Q3 		$216K Buy
+42,039
New +$275K ﹤0.01% 5428
2022
Q3 		– Sell
-94,036
Closed -$937K – 6456
2022
Q2 		$937K Buy
94,036
+35,700
+61% +$355K ﹤0.01% 4665
2022
Q1 		$578K Buy
+58,336
New +$576K ﹤0.01% 5222

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs's OBIO Position: Q1 2026 in Review

Goldman Sachs increased its Orchestra BioMed (OBIO) stake by 16% in Q1 2026, buying an estimated $90.1K and bringing the position to 155,242 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #5401.

Goldman Sachs first reported a position in OBIO in Q1 2022 and has held it in 9 quarters since. The position peaked at $937K in Q2 2022. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Goldman Sachs held 155,242 shares of Orchestra BioMed worth $660K as of Q1 2026.
  • Goldman Sachs bought 21,169 Orchestra BioMed shares in Q1 2026, an estimated $90.1K.
  • Orchestra BioMed made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5401 holding.
  • Goldman Sachs first reported a position in Orchestra BioMed in Q1 2022 and has held it in 9 quarters since.
  • Goldman Sachs's Orchestra BioMed position peaked at $937K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.